Tisotumab vedotin [TISV1]
For treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment where the following criteria have been met:
- This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
- This patient has a histological diagnosis of recurrent or metastatic cervical cancer, and has exhibited disease progression, either whilst receiving, or after treatment with, systemic chemotherapy.
Note
Note: The histology must be either squamous, adenocarcinoma, or adenosquamous.
- This patient has received either ONE or TWO prior lines of systemic treatment for their recurrent/metastatic cervical cancer. Please mark below how many prior lines of treatment have been received:
- ONE prior line
- TWO prior lines
- The patient has an ECOG performance status of 0 or 1 Please mark below the performance status of the patient:
- ECOG PS 0
- ECOG PS 1
- Treatment with tisotumab vedotin will be given until disease progression, unacceptable toxicity, or withdrawal of patient consent, whichever of these events occurs first.
- The prescribing clinician understands that given the potentially necessary frequency and duration of treatment breaks during treatment with tisotumab vedotin, this indication is exempt from NHS England’s treatment break policy
Note
Note: if there is disease progression during a treatment break from tisotumab vedotin, treatment with tisotumab vedotin must be discontinued.
- The use of tisotumab vedotin will be otherwise used as per its Summary of Product Characteristics (SPC).
CDF funded From: 21 May 2026
Additional information
Current Form Version
Important
This is an older version of the form. To view the most up to date form follow this link
Older Form Versions
There are previous versions of this form. These may not all be available on this site.Citation
BibTeX citation:
@misc{2026,
author = {},
title = {Tisotumab Vedotin: From the {NHS} {England} {CDF} {List}
(V1.399) {{[}TISV1{]}}},
number = {TISV1},
date = {2026-05-21},
url = {https://updates.chemo.org.uk/CDF_Forms/TISV1.html},
langid = {en}
}
For attribution, please cite this work as:
Tisotumab vedotin: from the NHS England CDF
List (v1.399) [TISV1]. Chemotherapy Updates. May 21, 2026. https://updates.chemo.org.uk/CDF_Forms/TISV1.html